Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Covishield

    Jump to

    • Stopped manufacturing, supply of Covishield vaccine since December 2021: Serum Institute

      The Indian drugmaker said it is committed to transparency and safety and had taken all the required steps to disclose the rare side effects of the vaccine

    • Shreyas Talpade says his heart attack could be the side effect of Covid vaccine, 'I would not negate the theory'

      Bollywood actor Shreyas Talpade says he believes that a reason for his ill health and massive heart attack in December, last year, could be a side effect of the 'Covishield Vaccine', now that the news of the vaccine causing blood clots has left many surprised.

    • AstraZeneca Pharma fall 3% despite healthy Q2 net profit, revenue growth

      The stock slipped amid reports of the Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, facing a legal challenge the UK

    • Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield

    • Covishield immune responses against Covid variants higher than Covaxin: Study

    • Serum Institute to start free COVID vaccine supply to government, other manufacturers await order

    • Serum Institute to provide 2 crore Covishield doses to central govt free of cost

    • Bill Gates, Serum Institute get Bombay HC notice after man claims Covishield side-effects killed daughter

    • HC seeks response from SII, others on plea demanding Rs 1,000 crore compensation for woman's death

    • Government nod to Corbevax as precaution dose for adults vaccinated with Covaxin, Covishield

    • Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

    • COVID-19 shots administered in India about to overtake count in all of Europe, North America

    • Top virologists weigh in for Corbevax booster after primary vaccination with Covishield, Covaxin 

    • World's biggest vaccine maker Serum halts production with 200 million doses spare

    • India's 'warm' vaccine candidate effective against Delta, Omicron variants in mice: Study

    • Reduce time gap for COVID vaccine booster dose to six months: Serum Institute to govt

    • SII to give free Covishield vials to private vaccination centres to compensate for price difference

    • Moneycontrol Daily: Your Essential 7

    • Covaxin, Covishield prices slashed to Rs 225 per shot, a day before precaution drive starts

    • For future orders, SII to provide free replacement if vaccine expires: Adar Poonawalla

    • Huge response to COVID-19 shots for 12-14 age group; private hospitals keep away

    • Explainer: Intranasal vaccine against COVID-19 and why it is awaited so eagerly

    • Adar Poonawalla, CEO of vaccine maker Serum Institute, has a message for Novak Djokovic

    • Piles of unused COVID-19 jabs near expiry, private hospitals turn to government for bailout

    • Centre spent Rs 28,436 crore on vaccination this fiscal, leaving 27% of the allocated fund unspent

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347